A new blood test provides a fast and accurate tool to diagnose tuberculosis in children, a new proof-of-concept study shows. The newly developed test (TAM-TB assay) is the first reliable immunodiagnostic assay to detect active tuberculosis in children. The test features excellent specificity, a similar sensitivity as culture tests in combination with speed of a blood test. The promising findings are a major advance for the diagnosis of tuberculosis in children, particularly in tuberculosis-endemic regions. The study was published Sept. 1, 2014 in Lancet Infectious Diseases.
Tuberculosis (TB) in children is a serious public health problem especially in low-resource countries. About one million children per year develop tuberculosis worldwide. Unfortunately, the diagnosis of paediatric TB poses a major challenge. TB symptoms in children are often non-specific and similar to those of common paediatric illnesses, including pneumonia and malnutrition. Further, obtaining adequate respiratory specimens for direct mycobacterial confirmation is problematic. Consequently, there is an urgent need for a more precise, rapid and affordable diagnostic test for childhood tuberculosis.
The new so-called TAM-TB assay is a sputum-independent blood test. It makes use of an immunological phenomenon during tuberculosis disease: During an active infection, the expression of CD27 – a surface marker expressed on mycobacteria specific CD4+ T cells – is lost. Using standard intracellular cytokine staining procedures and polychromatic flow cytometry, the test result is available within 24 hours after blood sampling.
The new test was assessed in tuberculosis endemic regions in Tanzania at the Ifakara Health Institute and the NIMR Mbeya Medical Research Center. Sputum and blood samples were obtained from children with tuberculosis symptoms to compare the performance of the new assay with culture tests. For the assessment of the diagnostic performance of the new test, the children were assigned to standardized clinical case classifications based on microbiological and clinical findings. The test proved to have a good sensitivity and excellent specificity.
"This rapid and reliable test has the great potential to significantly improve the diagnosis of active tuberculosis in children " says TB CHILD program manager Klaus Reither from the Swiss Tropical and Public Health Institute (Swiss TPH), who coordinated the study.
In a collaborative effort between Swiss TPH and Ludwigs-Maximilians-Universität München (LMU Munich), the test will now be further refined to optimise performance, particularly in HIV-infected children, and to reduce costs. The goal is to finally validate and implement a rapid, robust and accurate diagnostic test for active paediatric tuberculosis that can be used on the district level in resource-poor, tuberculosis-endemic countries.
The diagnostic assay was tested at the Ifakara Health Institute and the NIMR-Mbeya Medical Research Center in Tanzania coordinated by Klaus Reither from the Swiss Tropical and Public Health Institute (Swiss TPH) in collaboration with the clinical immunologists Claudia Daubenberger and Damien Portevin (both Swiss TPH), and Christof Geldmacher (LMU Munich).
The study was funded by European and Developing Countries Clinical Trials Partnership, German Federal Ministry of Education and Research, and Swiss National Science Foundation.
Source: Swiss Tropical and Public Health Institute (Swiss TPH)
Hiding in Plain Sight: The Most Harmful and Costly Hospital-Acquired Infection
February 5th 2025Nonventilator hospital-acquired pneumonia (NV-HAP) is a deadly, overlooked infection impacting patient outcomes. With new diagnostic tools and prevention strategies, hospitals must prioritize oral hygiene to reduce risk.
Gag Order Puts Public Health at Risk, APIC Urges Immediate Action
February 4th 2025APIC warns that the HHS gag order on CDC communications endangers public health, delaying critical infection updates and weakening outbreak response amid rising tuberculosis, avian flu, Ebola, and measles threats.
Breaking Barriers: The Future of HIV Prevention and the Fight for Widespread PrEP Access
January 31st 2025Despite medical advances, HIV prevention faces roadblocks—low PrEP adoption, stigma, and accessibility issues threaten progress. Experts push for innovative, long-acting solutions to end the epidemic.